Sangamo showcases progress in our pre-clinical programs at ASGCT.
Click here to view
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
LinkedIn
Twitter
ASH 2022
Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A
December 12th, 2022
Interim Safety and Efficacy Results From a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)
December 12th, 2022